Here we would like to recommend that in subjects with risk factors for NAFLD such as elevated ALT levels or obesity, using this lower cut-off point of our model is valuable as a screening tool. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.